



FOR IMMEDIATE RELEASE

“Xeris Pharmaceuticals Appoints Dr. Steven Prestrelski as Chief Scientific Officer”

Austin, Texas – February 1, 2011 - Xeris Pharmaceuticals (“Xeris”) announced today that Steven Prestrelski, Ph.D., MBA has joined the Company as its Chief Scientific Officer. As Chief Scientific Officer (COO), Dr. Prestrelski will be responsible for developing and managing the pipeline of products based on the Company’s XeriJect™ and XeriSol™ formulation technologies.

“As the inventor of our platform technologies and co-founder of Xeris, Steve is most intimately aware of the potential that this technology holds for changing the current formulation and delivery of many biologics,” stated John Kinzell, Ph.D., CEO of Xeris. “Steve has been a leader in the field of protein and peptide formulation and delivery. There is no one better to lead the technical development for Xeris and manage its pipeline of products.”

Dr. Prestrelski is an internationally recognized expert in drug formulation and delivery with over 20 years of product development experience. He was most recently Vice President of Pharmaceutical R&D at Amylin Pharmaceuticals. Previously, he was the Executive Director of the Bydureon® Program at Amylin, having led this program from Phase 2 through global regulatory filings. Prior to Amylin, he was Vice President, Biopharmaceuticals at PowderJect Technologies, Inc. where he pioneered the delivery of solid biopharmaceuticals. Dr. Prestrelski has published over 50 invited book chapters and peer reviewed journal articles. He has over 10 issued and 12 pending patent applications in the field of drug formulation and delivery. Dr. Prestrelski has a PhD in Molecular Biophysics from the City University of New York and an MBA from Rady School of Business at the University of California, San Diego.

About XERIS

XERIS develops patient-friendly injectables based on its XeriJect™ and XeriSol™ formulation and delivery platforms. The company’s products are ultra-low-volume, injectable bio-pharmaceuticals packaged in an auto-injector pen that patients and their caregivers can use at home or work. Bio-pharmaceuticals are the fastest growing category of therapeutics and are forecasted to be 6 of the top 10 drugs by 2014. The current paradigm of delivery requires nearly all of these drugs to be administered by injection or infusion, often in a clinical setting, decreasing compliance, increasing cost and providing a terrible patient experience. Xeris aspires to change this paradigm by developing ultra-low volume, ready-to-use bio-pharmaceuticals delivered through patient-friendly injectable devices, many of which would be self-administered in the comfort of the patient’s home. Products built on Xeris’ technologies would simplify administration and ease the pain of injections, improving the experience for hundreds of millions of patients. For more information, visit www.xerispharma.com.

SOURCE - Xeris Pharmaceuticals, Inc.

###